Merck Serono S A

GENEVA, December 13, 2011 - Number of donated tablets doubled to around 50 millionper year Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced its intention to further boost its efforts in the fight against the tropical disease schistosomiasis and to continue until the disease has been officially eliminated in Africa.

GENEVA, November 30, 2011 - Winning idea highlights need for innovative solutions for people living with multiple sclerosis Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced Brian Light of Toronto, Canada as the overall winner of the "Real MS: Your Innovation" campaign, a global design competition that challenged the multiple sclerosis (MS) community to submit unique and innovative ideas to help people overcome the daily challenges of life with MS.

GENEVA, November 18, 2011 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for its variation application to extend the indication of Rebif (interferon beta-1a), its leading treatment for relapsing forms of multiple sclerosis (MS).

GENEVA, November 14, 2011 - Merck Serono to run awareness activities for the prevention of Type 2 diabetes The company has a strong heritage in providing treatment for Type 2 diabetes extending over fifty years Merck Serono markets Glucophage, the worldwide leading brand in volumes of metformin[1], which is recommended by the IDF as the first-line treatment for type 2 diabetes[2] Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announces that the company is participating in World Diabetes Day (WDD), a global awareness campaign initiated by the International Diabetes Federation (IDF), taking place every year on 14 November[3].

GENEVA, November 9, 2011 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has further expanded its relationship with Ablynx and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis.